Table 3. Studies assessing effectiveness of bDMARDs in patients with polyarticular JIA.
| Author | Year Published | Data Source | Patient Population | Sample Size | Major Findings |
|---|---|---|---|---|---|
| Horneff et al. (31) | 2016 | German BIKER Registry | Polyarticular JIA | 729 Patients (ETA 419, ADA 236, TOC n = 74). | Pediatric ACR30/50/70/90 improvement was achieved by ETA (68%/60%/42%/24%), ADA (67%/59%/43%/27%) and TOC (61%/52%/35%/26%) in 3 months. JADAS minimal disease activity was achieved by ETA (61.3%), ADA (52.4%) and TOC (52.4%) in 24 months. JADAS remission was achieved in ETA (34.8%), ADA (27.9%) and TOC (27.9%). There were no statistically significant differences between the three groups in these outcomes, after adjusting for baseline differences between the three cohorts. Lastly, ETA (49.4%), ADA (60.4%), and TOC (31.1%) of patients discontinued therapy, respectively. |
| Thiele et al. (32) | 2023 | German BIKER Registry | Polyarticular JIA | 2,148 Patients (684 bDMARD monotherapy, 1,464 combination with MTX) | A significant decline in disease activity among patients undergoing MTX combination vs. bDMARD monotherapy. Patients who received TNFi experienced greater benefits from the additional MTX compared to patients receiving TOC. Median survival time of bDMARD was significantly longer in the combination group (3.1 years) than in the monotherapy group (2.7 years). |
| Yue et al. (34) | 2021 | EMR of Cincinnati Children Hospital | Non-sJIA | 667 patients | Median persistence of the first-line bDMARD is 320 days, with TNFi having longer persistence than the non-TNFi (395 vs. 320 days). Reduction in the clinical Juvenile Disease Activity Score (cJADAS) of TNFi users was significantly higher than non-TNFi users (6.6 vs. 3.0) during a 6-month follow-up. |
| van Straalen et al. (35) | 2022 | International Pharmachild Registry | Non-sJIA | 134 patients before propensity sore matching (45 ETA and ADA matched patients) | The estimated mean difference in changes in visual analogue scale (VAS) well-being score from baseline for ETA versus ADA was 0.89 (95% CI: -0.01 - 1.78; p = 0.06). Both ETA and ADA improved patient-reported well-being in non-systemic JIA, with a slightly stronger effect for ETA. |
| Kip et al. (36) | 2023 | EMR of Wilhelmina Children's Hospital | Non-sJIA | 236 patients | Remission was the most common reason for both bDMARD and csDMARD discontinuation (44.7%), followed by AEs (28.9%) and ineffectiveness (22.1%). |